Anti-angiogenic active immunotherapy: a new approach to cancer treatment.
Tumor angiogenesis plays an important role in tumor growth, aggression and metastasis. Many molecules have been demonstrated as positive regulators of angiogenesis, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), and others. In recent years, significant progress has been made in the research on anti-angiogenic strategies for tumor therapies. In this review, anti-angiogenic active immunotherapies for tumors based on vaccination with xenogeneic homologous molecules and non-xenogeneic homologous molecules are discussed.
Pan
Jianping
J
Department of Medical Microbiology and Parasitology, Zhejiang University School of Medicine, 388 Yuhangtang Road, Hangzhou, 310058, People's Republic of China. jppan@zju.edu.cn
Jin
Pengfeng
P
Yan
Jie
J
Kabelitz
Dieter
D
D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors; D005346:Fibroblast Growth Factors / Q000037:antagonists & inhibitors; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000276:immunology*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D019496:Cancer Vaccines; D042461:Vascular Endothelial Growth Factor A; D005346:Fibroblast Growth Factors; D004815:Epidermal Growth Factor